Comparison of injectable anticoagulants for thromboprophylaxis after cancer-related surgery

American Journal of Health-System Pharmacy

Volumn 71, Issue 7, 2014, Pages 562-569

  Changolkar, Arun ^a,b   Menditto, Laura ^b,c   Shah, Manan ^d,e   Puto, Katarzyna ^f,g   Farrelly, Eileen ^h  

^a SOAL Pharmatech Solutions Inc   (United States)

^b GLAXOSMITHKLINE   (United States)

^c Laura A Menditto LLC   (United States)

^d Bristol Myers Squibb   (United States)

^e XCENDA   (United States)

^f Global Health Economics and Outcomes Research   (United States)

^g Xcenda   (United States)

^h Xcenda   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; ANTICOAGULANT AGENT;

ADULT; ARTICLE; BLEEDING; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; HOSPITAL READMISSION; HOSPITALIZATION COST; HUMAN; LENGTH OF STAY; LUNG EMBOLISM; MAJOR BLEEDING; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PROPENSITY SCORE; RETROSPECTIVE STUDY; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; COMPARATIVE STUDY; FEMALE; HEALTH CARE COST; INJECTION; MALE; MIDDLE AGED; NEOPLASMS; POSTOPERATIVE COMPLICATIONS;

ANTICOAGULANTS; COHORT STUDIES; ENOXAPARIN; FEMALE; HEALTH CARE COSTS; HEPARIN; HUMANS; INJECTIONS; MALE; MIDDLE AGED; NEOPLASMS; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM;

EID: 84907213055     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp120711     Document Type: Article

References (27)

1. Khorana AA, Francis CW, Culakova E et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007; 5:632-4.
2. Mandala M, Falanga A, Roila F, on behalf of the ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO clinical practice guidelines. Ann Oncol. 2001; 22(suppl 6):vi-85-92.
3. Khorana AA, Francis CW, Culakova E et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006; 24:484-90.
4. Khosravi-Shahi P, Perez-Manga G. International recommendations for the prevention and treatment of venous thromboembolism associated with cancer. Clin Drug Investig. 2009; 29:625-33.
5. Rodrigues CA, Ferrarotto R, Filho RK et al. Venous thromboembolism and cancer: a systemic review. J Thromb Thrombolysis. 2010; 30:67-78.
6. Guyatt GH, Akl EA, Crowther M et al. Antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(suppl):1S-119S.
7. Negus JJ, Gardner JJ, Tann O et al. Thromboprophylaxis in major abdominal surgery. Eur J Surg Oncol. 2006; 32:911-6.
8. Spyropoulos AC, Brotman AD, Amin AN et al. Prevention of venous thromboembolism in the cancer surgery patient. Cleve Clin J Med. 2008; 75(suppl 3):S17-26.
9. Hass S, Wolf H, Kakkar AK et al. Prevention of fatal pulmonary embolism and mortality in surgical patients. A randomized double-blind comparison of LMWH with unfractionated heparin. Thromb Haemost. 2005; 94:814-9.
10. Stein PD, Beemath A, Meyers FA et al. Incidence of venous thromboembolism in patients hospitalized with cancer. Am J Med. 2006; 119:60-8.
11. Khorana AA, Streiff MB, Falanga A et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol. 2009; 29:4919-26.
12. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery. A double-blind randomized multicentre trial with venographic assessment. Br J Surg. 1997; 84:1099-103.
13. McLeod RS, Geerts WH, Sniderman KW et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results from the Canadian colorectal DVT prophylaxis trial. A randomized, double-blind trial. Ann Surg. 2001; 233:438-44.
14. National Comprehensive Cancer Network (NCCN) practice guidelines in oncology. Venous thromboembolic disease, v.1.2010. www.nccn.org (accessed 2010 Aug 14).
15. Arixtra (fondaparinux sodium) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2012 Jan.
16. Angelli G, Bergqvist D, Cohen AT et al., on behalf of the PEGASUS investigators. Randomized clinical trial of post-operative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg. 2005; 92:1212-20.
17. Turpie AG, Bauer KA, Caprini JA et al., on behalf of the APOLLO investigators. Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. J Thromb Haemost. 2007; 5:1854-61.
18. Blanchette CM, Wang PF, Joshi AV et al. Resource utilization and costs of blood management services associated with knee and hip surgeries in US hospitals. Adv Ther. 2006; 23:54-67.
19. Blanchette C, Wang P, Joshi A et al. Cost and utilization of blood transfusion associated with spinal surgeries in the United States. Eur Spine J. 2007; 16:353-63.
20. Lindenauer PK, Pekow P, Wang K et al. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med. 2005; 353:349-61.
21. Orrick JJ, Segal R, Johns TE et al. Resource use and cost of care for patients hospitalized with community acquired pneumonia: impact on adherence to Infectious Diseases Society of America guidelines. Pharmacoeconomics. 2004; 22:751-7.
22. Ouriel K, Kaul AF, Leonard MC. Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis. J Vasc Surg. 2004; 40:971-7.
23. Shorr AF, Sarnes MW, Peeples PJ et al. Comparison of cost, effectiveness and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery. Am J Health-Syst Pharm. 2007; 64:2349-55.
24. Leonardi MJ, McGory ML, Ko CY. A systemic review of deep venous thrombosis prophylaxis in cancer patients: implications for improving quality. Ann Surg Oncol. 2006; 14:929-36.
25. Sullivan SD, Davidson BL, Kahn SR et al. A cost-effectiveness analysis of fondaparinux sodium compared to enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmacoeconomics. 2004; 22:605-20.
26. Merli GJ, Ferrufino C, Lin J et al. Total hospital-based costs of enoxaparin or fondaparinux prophylaxis in patients at risk of venous thromboembolism. Poster presented at the CHEST Annual Meeting. Philadelphia, PA; 2008 Oct.
27. Wade WE, Spruill WJ, Leslie RB. Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in hip fracture surgery. Am J Ther. 2004; 11:194-8.